bioAffinity Technologies (BIAF) Depreciation & Amortization (CF) (2021 - 2026)

bioAffinity Technologies has disclosed Depreciation & Amortization (CF) across 6 years of filings, most recently posting $114518.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 25.92% year-over-year to $114518.0; the TTM figure through Mar 2026 stood at $464766.0 (down 23.88% YoY), while the FY2025 annual figure was $504836.0, down 16.64% from the prior year.
• Depreciation & Amortization (CF) eased to $114518.0 in Q1 2026, from $123659.0 in the prior quarter.
• Over the last five years, Depreciation & Amortization (CF) for BIAF reached as high as $154588.0 in Q1 2025 and fell as low as $773.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $113360.0 (2025), against an average of $87339.1.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) soared 7347.48% — and 2026, when it decreased 25.92%.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $7330.0 in 2022, then surged by 1929.84% to $148787.0 in 2023, then increased by 3.26% to $153632.0 in 2024, then retreated by 19.51% to $123659.0 in 2025, then dropped by 7.39% to $114518.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $114518.0, $123659.0, and $113360.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.